Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2023 third-quarter earnings
A cartoon displaying multiple different types of charts and graphs

What you need to know about Johnson & Johnson’s 2023 third-quarter earnings

Check out this infographic breakdown of the company’s third-quarter 2023 performance, with key highlights from its Innovative Medicine and MedTech businesses.

This morning, Johnson & Johnson shared its third-quarter 2023 performance.

Since its founding in 1886, the company has grown to become the world’s largest, most diversified healthcare products company, with more than 130,000 employees across the globe working every day to help change the trajectory of health for humanity.

This Q3 2023 infographic further highlights how Johnson & Johnson continues to progress its long-term operational and financial priorities and deliver value to its stakeholders.

“We are confident that Johnson & Johnson’s strong performance through the first nine months of this year will continue, and as a result, we have increased our guidance for 2023,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “The strength of our business, the promise of our Innovative Medicine and MedTech pipelines, and our 130,000 colleagues around the world position us well for long-term growth and significant value creation for shareholders.”

For more details about the company’s 2023 third-quarter results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


Johnson & Johnson 2023 Q3 Earnings infographic

Johnson & Johnson’s 2023 3rd-Quarter Earnings

Read the earnings press release, which includes full financial data for the third quarter of 2023.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.